Cantor Fitzgerald Maintains Overweight on Aptose Biosciences, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on Aptose Biosciences (NASDAQ:APTO) and raises the price target from $6 to $38.
June 12, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on Aptose Biosciences and raises the price target from $6 to $38.
The news of Cantor Fitzgerald maintaining an Overweight rating on Aptose Biosciences and raising the price target from $6 to $38 is positive for the stock. This indicates that the analyst has a bullish outlook on the company's performance and potential growth. As a result, this news is likely to have a positive short-term impact on APTO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100